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Abstract
Purpose To evaluate the relationship between duration of mac-
ular edema associated with retinal vein occlusion (RVO) and the
achievement of vision gain in patients receiving dexamethasone
intravitreal implant (DEX implant) in real-world clinical practice,
and to define patterns of use of DEX implant and its efficacy and
safety in the treatment of patients with RVO in clinical practice.
Methods This prospective, open-label, multicenter, 6-month ob-
servational phase IV study conducted at 70 sites in Germany
enrolled patients diagnosed with macular edema following
branch or central RVO (BRVO, CRVO) who were given DEX
implant. Follow-up visits and evaluations occurred in accordance
with normal clinical practice. Re-treatment with DEX implant
and use of other RVO therapies was at the discretion of the
treating physician. The primary endpoint was mean change in
best-corrected visual acuity (BCVA) from baseline at week 12.
Results The analysis population consisted of 573 patients (64 %
BRVO, 36 % CRVO). Patients received a mean of 1.17 DEX
implant treatments during the study period; 84.3 % of patients
received a single DEX implant and 19.9 % received adjunctive
other RVO treatment. Among patients with analyzable BCVA
data at baseline and week 12 (n=351), mean change from base-
line BCVA at week 12 was −0.16 (standard deviation, 0.30)
logMAR (+7.8 approximate Early Treatment Diabetic
Retinopathy Study [ETDRS] letters) (p<0.001), and 33.9 % of
patients had gained at least 3 lines in BCVA from baseline.Mean
change from baseline BCVA at week 12 was +9.5, +7.3, and
+5.4 approximate ETDRS letters in patients with macular edema
duration<90 days, from 90 to 180 days, and >180 days respec-
tively. Improvement in BCVA through week 24 and decreases in
central retinal thickness were seen in both BRVO and CRVO.
The most common adverse drug reaction was increased intraoc-
ular pressure. No glaucoma incisional surgeries were required.
Conclusions DEX implant was effective in improving BCVA
and central retinal thickness in patients with BRVO and CRVO
in real-world clinical practice. The largest gains in BCVA over
6 months occurred in patients with recent onset macular edema,
confirming the benefit of early treatment. DEX implant was well
tolerated and had an acceptable safety profile.
Keywords Branch retinal vein occlusion . Central retinal
thickness . Central retinal vein occlusion . Dexamethasone .
Intravitreal . Macular edema
Introduction
Macular edema (ME) after a central or branch retinal vein
occlusion (CRVO, BRVO) is a common cause of vision loss
[1]. Treatment options include laser in BRVO and intravitreal
corticosteroids and antagonists of vascular endothelial growth
factor (anti-VEGF) in both BRVO and CRVO [2].
Dexamethasone intravitreal implant 0.7 mg (DEX implant;
Members of the German Ozurdex in RVO Real World Study Group are
listed in the Appendix
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Ozurdex, Allergan plc, Dublin, Ireland) provides sustained
release of the potent corticosteroid dexamethasone [3].
DEX implant was the first medical therapy approved for
treatment ofME associated with retinal vein occlusion (RVO).
In phase III clinical trials, a single treatment withDEX implant
effectively improved best-corrected visual acuity (BCVA) and
reduced central retinal thickness (CRT) in patients with ME
following RVO [4]. Clinically significant improvements in
BCVA and CRTafter DEX implant treatment weremost likely
in patients with ME of shorter duration [5]. In patients who
received a second implant after 6 months, re-treatment dem-
onstrated efficacy and safety similar to initial treatment, ex-
cept for an increase in reports of cataract after the second
implant [6]. Cataract and increased intraocular pressure
(IOP) are the most common side effects of DEX implant treat-
ment [6, 7].
Randomized clinical trials can provide high-quality evi-
dence of the efficacy of a treatment; these trials typically mea-
sure efficacy in carefully selected patient populations with
standardization of treatment and follow-up assessments.
However, in the population at large, patients are generally less
healthy with potentially confounding comorbidities, their use
of the treatment of interest may vary, and they may receive
other types of treatment as well. Therefore, observational stud-
ies of the use of a treatment in clinical practice provide addi-
tional valuable information concerning patterns of use and the
effectiveness of a treatment in a real-life setting. The results of
such studies can be extrapolated to a broader population com-
pared with randomized clinical trials.
The purpose of the present study was to evaluate the rela-
tionship between duration of RVO-associated ME and the
achievement of vision gain in patients receiving DEX implant
in real-world clinical practice. A secondary objective was to
define patterns of use of DEX implant and its efficacy and
safety in the treatment of patients with RVO in clinical practice.
Methods
This prospective, open-label, multicenter, 6-month observation-
al study was carried out in Germany from April 2012 through
June 2014. The study was conducted in accordance with the
tenets of the Declaration of Helsinki and Good Clinical
Practice, and was approved by the Landesärztekammer
Rheinland–Pfalz Independent Ethics Committee. Informed
consent was obtained from all individual participants included
in the study. The study is registered with the identifier
NCT01571557 at ClinicalTrials.gov.
To be included in the study, patients were required to be
≥18 years of age, diagnosed with ME following RVO, and
prescribed DEX implant. Patients were required to provide
written informed consent. The only exclusion criterion was
previous treatment with DEX implant.
Consecutive patients who met the patient eligibility criteria
were enrolled, and DEX implant was administered after eval-
uations on day 1 (baseline). Follow-up visits and evaluations
occurred in accordance with normal clinical practice. Any re-
treatment with DEX implant was to be consistent with the
Summary of Product Characteristics (SPC) and the treating
physician’s normal clinical practice.
Data collected at the baseline visit included demographics,
type of RVO, date of onset of ME symptoms, date of RVO
diagnosis, ophthalmic history, lens status, and previous therapy
for RVO. Efficacy was evaluated by BCVA and CRTon optical
coherence tomography (OCT) at baseline and each follow-up
visit. CRT could be measured on either time-domain or
spectral-domain OCT. The primary endpoint was mean change
in BCVA from baseline at week 12. Key secondary efficacy
outcome measures were mean change from baseline BCVA at
each visit, mean BCVA at each visit, the percentage of patients
achieving≥2-line gain in BCVA from baseline at week 12, and
mean change from baseline CRT at each visit. Other outcome
measures included use of DEX implant injections and other
treatments for RVO during the study, use of concomitant oph-
thalmic medication, ocular surgeries, IOP, and adverse drug
reactions (ADRs) (primary safety outcome measure).
Patient and physician satisfaction, tolerability of DEX im-
plant, and continuation of treatment were evaluated at the final
visit. The patient and physician were asked to rate their overall
satisfaction with the DEX implant treatment as “very good”,
“good”, “moderate”, or “insufficient”. The tolerability of
DEX implant treatment was rated by both the patient and
physician, with possible responses of “very good”, “good”,
“moderate”, or “bad”. The physician also was asked whether
the patient would receive additional DEX implant injections.
Snellen BCVAwas converted to logMAR and to approxi-
mate Early Treatment Diabetic Retinopathy Study
(approxETDRS) letters for analysis [8]. Visual acuity assess-
ments based on finger count or handmotion were not assigned
a Snellen value, and consequently were excluded from analy-
sis. Analysis of change in BCVA or CRT from baseline at a
particular visit was based on patients with data at both baseline
and that visit. All analyses used observed values (no imputa-
tion for missing values) in the analysis population of all pa-
tients with no protocol violations.When values were available
from multiple visits within a visit window, the value from the
visit showing greatest improvement (peak drug effect) was
used in the analysis.
Subgroup analysis was performed for patient sub-
groups defined by diagnosis (BRVO or CRVO), the du-
ration of ME at baseline (<90 days, 90–180 days, or
>180 days), treatment for RVO used during the study,
previous treatment for RVO, and perfusion status. The
duration of ME at baseline was determined using the
onset of symptoms (the date when the patient first be-
came aware of a decrease in visual acuity) as the start
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date of the ME. Due to the observational nature of this
study and the variable timing and number of follow-up
visits, data from visits within a defined timeframe were
grouped for analysis. The windows used for visits were
week 6: days 2–63, week 12: days 64–126, and week 24
(month 6): days 127–210. Additional visit windows for
patients with data collected for longer than 6 months
were week 36: days 211–294, and week 48: day 295–
last day in study. These data were not requested by the
protocol; however, due to the observational nature of the
study, some such data were provided.
Statistical analysis was performed using SAS 9.1.3 or 9.3
software (SAS Institute Inc., Cary, NC, USA) and observed
values in the dataset of all available data. The Wilcoxon
signed rank test was used to test for changes in mean BCVA




A total of 623 patients were enrolled in the study from April
2012 through December 2013. Fifty patients were excluded
from analysis due to protocol violations (no DEX implant
treatment at the baseline visit, n=32; had been treated previ-
ously with DEX implant, n=14; informed consent signed
after the initial DEX implant treatment, n=2; or missing doc-
umentation of study eye, n= 1) or to data errors (n = 1).
Therefore, the analysis population consisted of 573 patients
from 70 sites in Germany.
Five hundred nineteen patients in the analysis
population (90.6 %) had at least one documented
follow-up visit. Data availability for these patients with-
in the predefined visit windows is shown in Table 1.
The study duration (period of data collection and
analysis) was more than 24 weeks for some patients,
but the typical period of follow-up was 6 months, with
316 patients (60.9 % of patients with at least one
follow-up visit) seen within the month-6 visit window.
The mean time from baseline to the last follow-up visit
with data collection was 155 days (range, 1–656).
Baseline characteristics of patients and study eyes in
the analysis populat ion are l is ted in Table 2.
Approximately two-thirds of the analysis population
(64 %) was diagnosed with BRVO and one-third
(36 %) with CRVO. Visual acuity in the study eye
ranged from “hand motion” (in 15 patients) and “finger
counting” (in 12 patients) to better than 20/20 Snellen.
Baseline mean Snellen visual acuity was 0.67 logMAR
(approximately 20/100) in the total analysis population,
0.61 logMAR (20/80) in patients with BRVO, and 0.79
logMAR (20/125) in patients with CRVO. Patients with
an ophthalmic history of other disease that could affect
vision, such as age-related macular degeneration and
diabetic retinopathy, were not excluded, and in some
cases visual acuity could have been affected by the
presence of other macular disease. Approximately
8.2 % (47/573) of patients were re- ported to have con-
current diabetes mellitus. Fifty-six patients (9.8 %) were
diagnosed with glaucoma in the study eye.
The median time since the onset of ME symptoms
was approximately 3 months (98 days in BRVO patients
and 94.5 days in CRVO patients). The RVO was
reported to be ischemic in 22 % of study eyes (20.2 %
of eyes with BRVO and 25.2 % of eyes with CRVO).
Baseline mean CRT was 501 μm (476 μm in BRVO
patients and 546 μm in CRVO patients).
Treatment
During the study, 668 DEX implant treatments were adminis-
tered. The mean number of DEX implant treatments per
Table 1 Data availability for the
analysis population within visit
windows















Baseline 573 566 378
Week 6 436 436 38 172 42
Week 12 380 380 95 198 95
Week 24 316 316 161 158 158
Week 36 87 87 240 37 238
Week 48 26 26 369 11 363
BCVA best-corrected visual acuity, OCT optical coherence tomography
a Visit windows were baseline: day 1; week 6: days 2–63; week 12: days 64–126; and week 24: days 127–210.
Additional visit windows for patients who had data collected beyond the 6 months called for in the study protocol
were week 36: days 211–294 and week 48: day 295–last day in study
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patient was 1.17 in the analysis population, 1.18 in patients
with BRVO, and 1.14 in patients with CRVO. The number
and timing of DEX implant treatments received by patients is
shown in Table 3. The majority of patients (483/573, 84.3 %)
received a single DEX implant during the study period. For
the 85 patients who received a second DEX implant treatment,
the mean time between the first and second implant injections
was 155 days (range, 59–378). Five patients who were in the
Table 2 Baseline patient






Mean age, years (SD) 72.1 (10.6) 72.1 (10.6) 72.2 (10.4)
Range 35–94 35–94 40–89
Gender, n (%)
Male 287 (50.1) 177 (48.2) 110 (53.4)
Female 286 (49.9) 190 (51.8) 96 (46.6)




Yes 126 (22.0) 74 (20.2) 52 (25.2)
No 447 (78.0) 293 (79.8) 154 (74.8)
Median days since onset of
ME symptoms
97 98 94.5
< 90 days, n (%) 268 (46.8) 170 (46.3) 98 (47.6)
90–180 days, n (%) 99 (17.3) 57 (15.5) 42 (20.4)
> 180 days, n (%) 206 (36.0) 140 (38.2) 66 (32.0)
Lens status in study eye, n (%)
Phakic 312 (54.5) 189 (51.5) 123 (59.7)
Pseudophakic 42 (7.3) 26 (7.1) 16 (7.8)
Not reporteda 219 (38.2) 152 (41.4) 67 (32.5)
Glaucoma in study eye, n (%) 56 (9.8) 35 (9.5) 21 (10.2)
Mean BCVA, logMAR (SD)b 0.67 (0.39) 0.61 (0.36) 0.79 (0.41)
Approximate Snellen 20/100 20/80 20/125
Approximate ETDRS letter score 51 54 45
Mean CRT, μm (SD) 501 (169) 476 (145) 546 (198)
History of previous RVO treatment
(study eye), n (%)
Yes 234 (40.8) 147 (40.1) 87 (42.2)
Procedurec 110 (19.2) 74 (20.2) 36 (17.5)
Drug-based therapy 215 (37.5) 135 (36.8) 80 (38.8)
Bevacizumab 126 (22.0) 80 (21.8) 46 (22.3)
Ranibizumab 90 (15.7) 56 (15.3) 34 (16.5)
Triamcinolone acetonide 10 (1.7) 2 (0.5) 8 (3.9)
Other 38 (6.6) 22 (6.0) 16 (7.8)
No 319 (55.7) 210 (57.2) 109 (52.9)
Not reported 20 (3.5) 10 (2.7) 10 (4.9)
BCVA best-corrected visual acuity, BRVO branch retinal vein occlusion, CRT central retinal thickness, CRVO
central retinal vein occlusion, ETDRS Early Treatment Diabetic Retinopathy Study, ME macular edema, RVO
retinal vein occlusion, SD standard deviation
a In 160 cases, the investigator indicated pseudophakic lens status but did not specify whether the patient was
pseudophakic in the study eye, the nonstudy eye, or both eyes
b Twenty-seven patients with best visual function determined as “count fingers” or “hand motion”were excluded
from the analysis of BCVA
c Focal laser, pan-retinal photocoagulation, and/or other procedure
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study for much longer than 6 months received a third DEX
implant treatment. The mean time between the first and third
implant in these patients was 314 days (range, 237–405)
(Table 3).
Most patients received only DEX implant for treatment of
their RVO during the study period, but approximately one in
five patients (114/573, 19.9 %) also received other types of
RVO treatment, most commonly laser (83/573, 14.5 % of
patients) or intravitreal anti-VEGF (26/573, 4.5 % of patients)
(Table 4).
EfficacyVisual outcomes
Mean BCVA in the total patient population in each visit win-
dow is shown in Table 5. Mean BCVA increased significantly
from baseline to week 12 (p<0.001) in patients with analyz-
able data in both visit windows. The mean change in BCVA
from baseline at week 12 (primary endpoint) was −0.16 (stan-
dard deviation [SD], 0.30) logMAR (+7.8 approxETDRS let-
ters) (n=351). Among patients with analyzable data in both
visit windows, 45.3 % gained at least 2 lines in BCVA and
33.9 % gained at least 3 lines in BCVA from baseline to week
12.
Improvement in BCVA from baseline was seen in the total
analysis population in each follow-up visit window (weeks 6,
12, and 24) (p<0.0001) (Fig. 1a). The change in BCVA from
baseline peaked at week 6 (Fig. 1a). Improvement in BCVA
through week 24 was seen in both BRVO and CRVO
(Fig. 1b).
A trend for greater gains in BCVA from baseline in patients
withMEofmore recent onset was evident (Fig. 1c). At week 12,
mean change from baseline BCVA was +9.5 approxETDRS
letters in patients with ME duration<90 days (n=174), +7.3
approxETDRS letters in patients with ME duration between
90 and 180 days (n=61), and +5.4 approxETDRS letters in
patients with ME duration>180 days (n=116). In both BRVO
and CRVO, there was a trend for better improvement in BCVA
when the duration of ME was <90 days versus>180 days
(Fig. 2).
Additional subgroup analysis showed significant im-
provement in BCVA in patients who received only DEX
implant treatment during the study period. The mean (SD)
change in BCVA from baseline to week 12 for these pa-
tients was −0.160 (0.299) logMAR or +8.0 approxETDRS
letters (n= 277). Improvement in BCVA in patients who
received only DEX implant treatment remained substan-
tial at week 24: the mean (SD) change in BCVA from
baseline to week 24 in these patients was −0.120 (0.301)
logMAR or +6.0 approxETDRS letters (n = 213). This
change from baseline BCVA was measured at a mean of
161 days (range, 126–206 days) after the baseline DEX
implant treatment.
Improvement in BCVA also was seen in patient sub-
groups defined by previous treatment and ischemia status.
Mean (SD) change from baseline BCVA at week 12 was
−0.087 (0.311) logMAR or +4.3 approxETDRS letters
(n= 134) in patients who had been treated previously with
any procedure or medication for RVO in the study eye
before study entry, and −0.080 (0.319) logMAR or +4.0
Table 3 Number and timing of








Number of DEX implant injections,
no. of patients (%)
1 483 (84.3) 305 (83.1) 178 (86.4)
2 85 (14.8) 58 (15.8) 27 (13.1)
3 5 (0.9) 4 (1.1) 1 (0.5)
For patients who received second
injection (n= 90 total):
Mean days from first to second
injection (SD)
155 (47) 151 (42) 164 (56)
Range 59–378 59–337 92–378
For patients who received third
injection (n= 5 total):
Mean days from first to third
injection (SD)
314 (74) 324 (82) 277 (NA)
Range 237–405 237–405 (NA)
Mean days from second to third
injection (SD)
166 (61) 178 (64) 120 (NA)
Range 105–245 105–245 (NA)
BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, DEX implant dexamethasone intravit-
real implant, NA not applicable, SD standard deviation
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approxETDRS letters (n= 105) in patients who had been
treated previously with anti-VEGF. In patients who were
treatment-naïve, mean (SD) change from baseline BCVA
at week 12 was −0.200 (0.286) logMAR or +10.0
approxETDRS letters (n= 204). Mean (SD) change from
baseline BCVA at week 12 was −0.117 (0.309) logMAR
or +5.9 approxETDRS letters (n= 75) in patients with is-
chemic RVO, and −0.166 (0.297) logMAR or +8.3
approxETDRS letters (n = 276) in patients with non-
ischemic RVO.
A substantial percentage of the patients demonstrated
clinically significant improvement in BCVA during the
study period. Overall, 47 % (267/573) of patients
gained≥ 2 lines in BCVA from baseline and 36 % (209/
573) gained ≥ 3 lines in BCVA from baseline at some
point during the study. The mean time to ≥2-line improve-
ment was 58 days (range, 1–312) and the mean time to
≥3-line improvement was 62 days (range, 1–312). These
outcomes were almost identical in the subgroups of pa-
tients with BRVO versus CRVO. Overall, 48 % of pa-
tients with BRVO and 45 % with CRVO gained at least
2 lines in BCVA, with a mean time to ≥2-line improve-
ment of 58 and 59 days respectively, whereas 36 % of
patients with BRVO and 37 % with CRVO gained at least
3 lines in BCVA, with a mean time to ≥3-line improve-
ment of 62 and 64 days.
Table 5 Mean BCVA in visit
windowsa Total analysis population (n= 573)
Visit windowb Mean logMAR (SD) Mean approximate ETDRS letters (SD)
Baseline (n= 539) 0.673 (0.387) 51.4 (19.3)
Week 6 (n= 418) 0.493 (0.378) 60.3 (18.9)
Week 12 (n= 365) 0.522 (0.414) 58.9 (20.7)
Week 24 (n= 297) 0.551 (0.426) 57.5 (21.3)
Week 36 (n= 81) 0.550 (0.457) 57.5 (22.8)
Week 48 (n= 24) 0.538 (0.447) 58.1 (22.3)
BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, SD standard deviation
a Mean values shown represent the mean for all patients with Snellen visual acuity data within the visit window.
Patients with visual acuity measurements based on finger count or hand motion were excluded from the analysis
b Visit windows were baseline: day 1; week 6: days 2–63; week 12: days 64–126; and week 24: days 127–210.
Additional visit windows for patients who had data collected beyond the 6 months called for in the study protocol
were week 36: days 211–294 and week 48: day 295–last day in study
Table 4 Other treatments for






Patients who used other RVO treatment in
addition to DEX implant
114 (19.9) 57 (15.5) 57 (27.7)
Type of other RVO treatment
Laser 83 (14.5) 47 (12.8) 36 (17.5)
Panretinal photocoagulation 25 (4.4) 7 (1.9) 18 (8.7)
Focal retinal laser 17 (3.0) 15 (4.1) 2 (1.0)
Grid laser, unspecified, or other 41 (7.2) 25 (6.8) 16 (7.8)
Anti-VEGF 26 (4.5) 12 (3.3) 14 (6.8)
Ranibizumab 14 (2.4) 8 (2.2) 6 (2.9)
Bevacizumab 10 (1.7) 3 (0.8) 7 (3.4)
Aflibercept 2 (0.3) 1 (0.3) 1 (0.5)
Pars plana vitrectomy 4 (0.7) 0 (0) 4 (1.9)
Cryocoagulation 4 (0.7) 0 (0) 4 (1.9)
Other 7 (1.2) 3 (0.8) 4 (1.9)
Unknown 9 (1.6) 3 (0.8) 6 (2.9)
Anti-VEGF vascular endothelial growth factor antagonist, BRVO branch retinal vein occlusion, CRVO central
retinal vein occlusion, DEX implant dexamethasone intravitreal implant, RVO retinal vein occlusion
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Anatomic outcomes
Three hundred and seventy-eight patients in the analysis pop-
ulation (66.0 %) had an OCT assessment at baseline. Over
90 % (91.1 %, 1047/1149) of the reported CRTmeasurements
at baseline and during follow-up were acquired with spectral-
domain OCT, and the remaining measurements were acquired
with time-domain OCT. Mean CRT decreased significantly
from baseline to week 6 in patients with CRT measurements
in both visit windows (p<0.001). The mean decrease in CRT
from baseline at week 6 in these patients was >200 μm
(Fig. 3a). The peak effect of DEX implant treatment on CRT
was at week 6, but mean CRT was also significantly reduced
from baseline at weeks 12 and 24 in patients with data in those
visit windows (p<0.001). Improvement in CRT was seen in
both BRVO and CRVO (Fig. 3b).
Safety
ADRswere reported in 43 patients (7.5%). Increased IOPwas
the only ADR reported in more than two patients; it was re-
ported in 33 patients (5.8 %). There was one serious ADR,
deterioration of pre-existing pseudoexfoliation glaucoma ne-
cessitating glaucoma laser surgery, in a patient with CRVO.
This ADR was rated by the physician as possibly related to
treatment.
At the baseline visit, mean IOP before and after the
DEX implant injection was 15.4 and 16.2 mmHg, re-
spectively. Seventy-five (13.2 %) of the 570 patients
with IOP measurements had IOP> 25 mmHg at some
point in the study. Fifty-five (9.6 %) of these patients
had IOP >25 mmHg during a single visit window, 13
(2.3 %) had IOP> 25 mmHg during two visit windows,
and seven (1.2 %) had IOP > 25 mmHg during three
visit windows.
Fig. 1 Mean change in best-corrected visual acuity from baseline in (a)
the total analysis population, (b) subgroups diagnosed with BRVO and
CRVO, and (c) subgroups defined by time since onset of ME symptoms.
Numbers in parentheses indicate number of patients (n). BRVO branch
retinal vein occlusion,CRVO central retinal vein occlusion, ETDRS Early
Treatment Diabetic Retinopathy Study, ME macular edema
Fig. 2 Mean change in best-corrected visual acuity from baseline by time
since onset of ME symptoms in (a) patients with BRVO and (b) patients
with CRVO. Numbers in parentheses indicate number of patients (n).
BRVO branch retinal vein occlusion, CRVO central retinal vein
occlusion, ETDRS Early Treatment Diabetic Retinopathy Study, ME
macular edema
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Increases in IOP were most commonly measured during
the week-6 visit window and were usually managed with top-
ical IOP-lowering medication. Among the 75 patients with an
IOPmeasurement>25mmHg, 21.3% had IOP>25mmHg at
the baseline visit, 58.7 % had IOP>25 mmHg during the
week-6 visit window, 38.7 % had IOP>25 mmHg during
the week-12 visit window, and 17.3 % had IOP>25 mmHg
during the week-24 visit window. IOP-lowering medication
was used by 7.3 % of patients at baseline and by 16.6 % of
patients during the study (Table 6). Among the 75 patients
with IOP> 25 mmHg during the study, 13 % used IOP-
lowering medication before starting DEX implant, 39 % be-
gan use of IOP-lowering medication during the study, and
48 % did not use IOP-lowering medication during the study.
No patients had glaucoma incisional surgery during the study
period, but nine patients underwent laser trabeculoplasty
(Table 6).
A cataract-related ADR was reported in only one eye
(0.3 % of baseline phakic eyes). Nineteen study eyes (6.1 %
of baseline phakic study eyes) underwent cataract extraction
during the study period.
Subjective assessments at study end
At the final study visit, physicians rated their satisfaction with
DEX implant treatment as “good” or “very good” in 65 % of
patients, “moderate” in 19 %, and “insufficient” in 7 % (data
were missing for 9 % of patients), and patients rated their
satisfaction with DEX implant treatment as “good” or “very
good” in 61 % of patients, “moderate” in 22 %, and “insuffi-
cient” in 8 % (data were missing for 9 % of patients).
Physicians rated the tolerability of DEX implant treatment as
“good” or “very good” in 84% of patients, “moderate” in 6%,
and “insufficient” in 0.2 % (data were missing for the remain-
ing patients). Patient ratings of tolerability were “good” or
“very good” in 84 % of patients, “moderate” in 6 %, and
“insufficient” in 0.5 % (data were missing for the remaining
patients). Among patients with a documented last visit, 53 %
were to receive additional DEX implant treatment and 23 %
were not to receive additional DEX implant treatment. Data
on continuation of treatment were missing for the remaining
24 % of patients.
Fig. 3 Mean change in central retinal thickness from baseline in (a) the
total analysis population and (b) subgroups diagnosed with BRVO and
CRVO. Error bars indicate standard deviation. Numbers in parentheses
indicate number of patients (n). BRVO branch retinal vein occlusion,
CRVO central retinal vein occlusion
Table 6 Treatment and
procedures for management of
IOP during the study period






Glaucoma incisional surgery 0 (0) 0 (0) 0 (0)
Laser trabeculoplasty 9 (1.6) 6 (1.6) 3 (1.5)
Among patients who had laser:
Baseline use of IOP-lowering medication 1 (11.1) 0 (0) 1 (33.3)
Started IOP-lowering medication during study 1 (11.1) 1 (16.7) 0 (0)
No use of IOP-lowering medication during study 7 (77.8) 5 (83.3) 2 (66.7)
Among all patients:
IOP-lowering medication used at baseline 42 (7.3) 21 (5.7) 21 (10.2)
IOP-lowering medication used during study 95 (16.6) 52 (14.2) 43 (20.9)
BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, IOP intraocular pressure
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Discussion
In this real-life observation study, DEX implant treatment im-
proved BCVA and CRT in patients with BRVO and CRVO. A
relationship between duration of ME and treatment efficacy
was observed, with larger gains in BCVA over 6 months in
patients with recent-onset ME, confirming the benefit of early
treatment. DEX implant treatment was well tolerated and had
an acceptable safety profile. Increases in IOP that occurred
were typically managed with topical medication; however,
even among patients with IOP>25 mmHg, 48 % did not use
IOP-lowering medication. No glaucoma incisional surgeries
were required during DEX implant treatment.
The mean BCVA gain of +7.8 approxETDRS letters (be-
tween 1 and 2 lines in visual acuity) at 12 weeks in this
study was similar to the gains in BCVA seen in previous
large retrospective studies of real-world use of DEX implant
in RVO [9, 10]. DEX implant was effective in patients pre-
viously treated with anti-VEGF, consistent with a previous
report that nine of ten patients with RVO ineffectively treat-
ed with anti-VEGF had improved BCVA and reduced CRT
after DEX implant treatment [11]. The relationship between
duration of ME and the efficacy of DEX implant treatment
seen in this study has also been reported in other studies. In
the SOLO retrospective 6-month study, DEX implant treat-
ment was associated with better improvement in CRT in
BRVO of shorter duration [12]. Furthermore, in the
GENEVA pivotal randomized clinical trials of DEX implant
for treatment of RVO-associated ME, shorter duration of
ME was associated with better improvement in BCVA and
CRT after DEX implant treatment, especially in patients with
BRVO [5].
The ADR profile of DEX implant in this study was also
consistent with previous reports, and increased IOP was the
most frequent adverse effect of treatment. Use of IOP-
lowering medication by patients in the study was consistent
with medication use in the 6-month GENEVA pivotal trials
of DEX implant in patients with RVO-associatedME, in which
the percentage of eyes receiving IOP-lowering medication in-
creased from6%at baseline to approximately 24% at 6months
[4], as well as with medication use in a retrospective study of
real-world use of DEX implant in Canada, in which 16.7 % of
patients with RVO-associated ME who were treated with DEX
implant required topical IOP-lowering medication [10]. A
slightly higher percentage of patients (29–34 %) were reported
to use or begin to use IOP-lowering medications in longer-term
retrospective studies of real-world use of two or more DEX
implant injections for treatment of RVO-associated ME in
Germany and the United States [9, 13]. The incidence of
steroid-related cataract progression was very low, probably be-
cause of the relatively short study duration of 6 months.
Cataract progression is more likely to be reported after multiple
implants and a longer duration of treatment [6, 14].
Previous studies have reported the time course of DEX
implant effects in RVO. In a prospective study in 19 eyes with
RVO-associated ME, improvement in BCVA and CRT was
shown to occur rapidly, with significant gains the day after
DEX implant treatment [15]. In the GENEVA study, improve-
ment in BCVAwas evident by 7 days after treatment, and 3-
line gains in visual acuity were maintained for 2–3 months
[16]. In this study, mean BCVA improvement peaked at week
6, then declined but remained significant through the month-6
visit window (day 127–210). The most likely explanation for
these findings is that for many patients, the optimal time for re-
treatment may be <6 months, yet 84.3 % of patients received
only one implant treatment during the study period.
When repeat treatment with DEX implant is indicated, the
timing of re-treatment varies; however, on average, an interval
shorter than 6 months is needed for sustained effectiveness
[17–20]. For patients who received a second implant in this
study, the mean time between the first and second implant was
155 days (approximately 5 months). This interval is consistent
with the interinjection interval of 4.5 months reported in a
prospective evaluation of DEX implant in patients with treat-
ment-naïve RVO [21], and with the interinjection interval of
5.6 months reported in the SHASTA study, a large retrospec-
tive evaluation in patients with BRVO and CRVO who re-
ceived at least two DEX implant injections [9]. The mean
interval between DEX implant treatments was approximately
5 months (151 days) for patients in the SHASTA study who
received no other treatment for RVO-associated ME during
the study period [22].
This study had several limitations. Evaluations were at the
discretion of the treating physician and according to normal
practice, so there was no standardization of assessments (e.g.,
in how ischemia was determined or CRTwas measured), and
many patients had missing data, particularly in anatomic mea-
surements. Although OCT provides information useful for
guiding treatment decisions in the management of RVO
[23], only 66 % of patients had an OCT assessment at base-
line, and OCTwas not performed regularly during follow-up,
presumably because OCT is not reimbursed in Germany. Data
on lens status also were missing for over one-third of patients.
Visit windows used for analysis were broad to allow analysis
of all available data, and on average, BCVA and OCT mea-
surements used for analysis in the week-12 visit window were
taken at 13.6 weeks, and those used for analysis in the month-
6 visit window were taken at 5.3 months. Although data were
collected for 6 months for most patients, some patients had
data collected over a longer study period and inclusion of
these data affected the analysis of number of treatments re-
ceived and may have affected the safety findings. Finally, use
of other RVO treatments was allowed and may have influ-
enced the efficacy and safety outcomes. However, the major-
ity of patients (80 %) used only DEX implant for treatment of
RVO during the study period.
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A decrease in the size of the study population over
time, due to discontinuations or loss to follow-up, is
common in phase IV trials and was seen in this study.
Only 316 patients (55.1 % of the analysis population)
had available BCVA data within the week-24 visit win-
dow. Nonetheless, improvement in BCVA from baseline
at week 24 was demonstrated for those patients who
had BCVA data at baseline and within the week-24 visit
window. Results of the analysis of changes in BCVA
and CRT over the course of the study should be
interpreted with caution, however, because at different
time points, different patients contributed data.
The study populations in randomized controlled trials
are typically carefully selected using eligibility criteria.
The value of this type of observational study is that the
effectiveness of treatment is evaluated in real-world use,
where patients have diverse medical histories and co-
morbidities. The results of this study complement the
results of previous randomized controlled trials and
demonstrate that DEX implant is effective in reducing
CRT and improving BCVA in real-world use.
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